Sofosbuvir and Ribavirin for Treatment of Chronic Hepatitis C in Patients Coinfected with Hepatitis C Virus and HIV: The Impact on Patient-Reported Outcomes

Journal of Infectious Diseases

Volumn 212, Issue 3, 2015, Pages 367-377

  Younossi, Zobair M ^a,b,h   Stepanova, Maria ^a,b,c   Sulkowski, Mark ^d   Naggie, Susanna ^e   Puoti, Massimo ^f   Orkin, Chloe ^g   Hunt, Sharon L ^a,b  

^a INOVA FAIRFAX HOSPITAL   (United States)

^b BETTY AND GUY BEATTY CENTER FOR INTEGRATED RESEARCH   (United States)

^c Center for Outcomes Research in Liver Diseases   (United States)

^d JOHNS HOPKINS UNIVERSITY   (United States)

^e DUKE UNIVERSITY MEDICAL CENTER   (United States)

^f OSPEDALE NIGUARDA CA GRANDA   (Italy)

^g BARTS HEALTH NHS TRUST   (United Kingdom)

^h Betty and Guy Beatty Center for Integrated Research Claude Moore Health Education and Research Bldg   (United States)

Author keywords

cirrhosis; HCV HIV coinfection; health related quality of life; Hepatitis C treatment; patient reported outcomes; ribavirin; sofosbuvir

Indexed keywords

RIBAVIRIN; SOFOSBUVIR; ANTIVIRUS AGENT; URIDINE PHOSPHATE;

ADULT; ANEMIA; ANTIVIRAL THERAPY; CHRONIC HEPATITIS C; CHRONIC LIVER DISEASE QUESTIONNAIRE HEPATITIS C VIRUS; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ASSESSMENT; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEMALE; FLU LIKE SYNDROME; FUNCTIONAL ASSESSMENT OF CHRONIC ILLNESS THERAPY FATIGUE; FUNCTIONAL STATUS ASSESSMENT; GASTROINTESTINAL SYMPTOM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; MIDDLE AGED; MIXED INFECTION; MUSCULOSKELETAL DISEASE; NEUROLOGIC DISEASE; OUTCOME ASSESSMENT; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; QUALITY OF LIFE; SHORT FORM 36; SKIN MANIFESTATION; TREATMENT DURATION; WORK PRODUCTIVITY AND ACTIVITY SPECIFIC HEALTH PROBLEM; ANALOGS AND DERIVATIVES; CLINICAL TRIAL; HEPATITIS C, CHRONIC; PATHOPHYSIOLOGY; PHASE 3 CLINICAL TRIAL; SELF REPORT; TREATMENT OUTCOME; VIROLOGY;

ANTIVIRAL AGENTS; COINFECTION; HEPATITIS C, CHRONIC; HIV INFECTIONS; HUMANS; LIVER CIRRHOSIS; QUALITY OF LIFE; RIBAVIRIN; SELF REPORT; TREATMENT OUTCOME; URIDINE MONOPHOSPHATE;

EID: 84936846257     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jiv005     Document Type: Conference Paper

References (49)

1. Kanwal F, Hoang T, Kramer JR, et al. Increasing prevalence of HCC and cirrhosis in patients with chronic hepatitis C virus infection. Gastroenterology 2011; 140:1182-8.e1.
2. Younossi ZM, Kanwal F, Saab S, et al. The impact of hepatitis C burden: An evidence-based approach. Aliment Pharmacol Ther 2014; 39:518-31.
3. Kallman J, O'Neil MM, Larive B, Boparai N, Calabrese L, Younossi ZM. Fatigue and health-related quality of life (HRQL) in chronic hepatitis C virus infection. Dig Dis Sci 2007; 52:2531-9.
4. Kabiri M, Jazwinski AB, Roberts MS, Schaefer AJ, Chhatwal J. The changing burden of hepatitis C virus infection in the United States: model-based predictions. Ann Intern Med 2014; 161:170-80.
5. Alter MJ. Epidemiology of viral hepatitis and HIV co-infection. J Hepatol 2006; 44(suppl 1):S6-9.
6. Denis F, Adjide CC, Rogez S, Delpeyroux C, Rogez JP,Weinbreck P. Seroprevalence of HBV, HCV and HDV hepatitis markers in 500 patients infected with the human immunodeficiency virus. Pathol Biol 1997; 45:701-8.
7. Roca B, Suarez I, Gonzalez J, et al. Hepatitis C virus and human immunodeficiency virus coinfection in Spain. J Infect 2003; 47:117-24.
8. Sherman KE, Rouster SD, Chung RT, Rajicic N. Hepatitis C virus prevalence among patients infected with human immunodeficiency virus: A cross-sectional analysis of the US Adult AIDS Clinical Trials Group. Clin Infect Dis 2002; 34:831-7.
9. Sulkowski MS, Thomas DL. Hepatitis C in the HIV-infected person. Ann Intern Med 2003; 138:197-207.
10. Urbanus AT, van de Laar TJ, Stolte IG, et al. Hepatitis C virus infections among HIV-infected men who have sex with men: An expanding epidemic. AIDS 2009; 23:F1-7.
11. Centers for Disease Control and Prevention (CDC). Sexual transmission of hepatitis C virus among HIV-infected men who have sex with men-New York City, 2005-2010. MMWR Morb Mortal Wkly Rep 2011; 60:945-50.
12. van der Helm JJ, Prins M, del Amo J, et al. The hepatitis C epidemic among HIV-positive MSM: incidence estimates from 1990 to 2007. AIDS 2011; 25:1083-91.
13. Eyster ME, FriedMW, Di Bisceglie AM, Goedert JJ. Increasing hepatitis C virus RNA levels in hemophiliacs: relationship to human immunodeficiency virus infection and liver disease. Multicenter Hemophilia Cohort Study. Blood 1994; 84:1020-3.
14. Thein HH, Yi Q, Dore GJ, Krahn MD. Natural history of hepatitis C virus infection in HIV-infected individuals and the impact of HIV in the era of highly active antiretroviral therapy: A meta-analysis. AIDS 2008; 22:1979-91.
15. Thein HH, Yi Q, Dore GJ, Krahn MD. Estimation of stage-specific fibrosis progression rates in chronic hepatitis C virus infection: A metaanalysis and meta-regression. Hepatology 2008; 48:418-31.
16. Lo Re V, Tate J, Kallan M, et al. Increased risk of hepatic decompensation and hepatocellular carcinoma in HIV/HCV-co-infected patients compared to HCV-mono-infected patients despite combination antiretroviral therapy [abstract WEAB0102]. Presented at: 19th International AIDS Conference, Washington, D. C., 2012. http://pag.aids2012.org/ Abstracts.aspx?SID=213&AID=17867. Accessed 25 September 2014.
17. Merchante N, Merino E, López-Aldeguer J, et al. Increasing incidence of hepatocellular carcinoma in HIV-infected patients in Spain. Clin Infect Dis 2013; 56:143-50.
18. Antiretroviral Therapy Cohort Collaboration. Life expectancy of individuals on combination antiretroviral therapy in high-income countries: A collaborative analysis of 14 cohort studies. Lancet 2008; 372: 293-9.
19. Knoll B, Lassmann B, Temesgen Z. Current status of HIV infection: A review for non-HIV-treating physicians. Int J Dermatol 2007; 46: 1219-28.
20. Morlat P, Roussillon C, Henard S, et al. Causes of death among HIVinfected patients in France in 2010 (national survey): Trends since 2000. AIDS 2014; 28:1181-91.
21. Weber R, Ruppik M, Rickenbach M, Spoerri A, Furrer H, Battegay M. Decreasing mortality and changing patterns of causes of death in the Swiss HIV Cohort Study. HIV Med 2013; 14:195-207.
22. Smith CJ, Ryom L,Weber R, et al. Trends in underlying causes of death in people with HIV from 1999 to 2011 (D:A:D): A multicohort collaboration. Lancet 2014; 384:241-8.
23. Hadziyannis SJ, Sette H Jr, Morgan TR, et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: A randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004; 140:346-55.
24. Torriani FJ, Rodriguez-Torres M, Rockstroh JK, et al. Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med 2004; 351:438-50.
25. Butt AA, Justice AC, Skanderson M, Good C, Kwoh CK. Rates and predictors of hepatitis C virus treatment in HIV/HCV-coinfected subjects. Aliment Pharmacol Ther 2006; 24:585-91.
26. Sulkowski MS, Sherman KE, Soriano V, et al. Telaprevir in combination with peginterferon alfa-2a/Ribavirin in HCV/HIV co-infected patients: SVR24 final study results. Hepatology 0000; 56(suppl 1):219A.
27. Jacobson IM, McHutchison JG, Dusheiko G, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011; 364:2405-16.
28. Poordad F, McCone J Jr, Bacon BR, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011; 364:1195-206.
29. Hézode C, Fontaine H, Dorival C, et al. Triple therapy in treatmentexperienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC)-NCT01514890. J Hepatol 2013; 59:434-41.
30. Gordon SC, Muir AJ, Lim JK, et al. Safety profile of boceprevir and telaprevir in chronic hepatitis C: real-world experience from HCV-TARGET. J Hepatol 2015; 62:286-93.
31. Sulkowski MS, Naggie S, Lalezari J, et al. Sofosbuvir and ribavirin for hepatitis C in patients with HIV coinfection. JAMA 2014; 312: 353-61.
32. Dieterich D, Rockstroh JK, Orkin C, et al. Simeprevir (TMC435) with peginterferon/ribavirin in patients coinfected with HCV genotype-1 and HIV-1: A phase III study. Clin Infect Dis 2014; 59:1579-87.
33. Younossi ZM, Stepanova M, Henry L, et al. Minimal impact of sofosbuvir and ribavirin on health related quality of life in Chronic Hepatitis C (CH-C). J Hepatol 2014; 60:741-7.
34. Younossi ZM, Stepanova M, Henry L, et al. Effects of sofosbuvir-based treatment, with and without interferon, on outcome and productivity of patients with chronic hepatitis C. Clin Gastroenterol Hepatol 2014; 12:1349-59.
35. Miners AH, Sabin CA, Mocroft A, Youle M, Fisher M, Johnson M. Health-related quality of life in individuals infected with HIV in the era of HAART. HIV Clin Trials 2001; 2:484-92.
36. Hays RD, Cunningham WE, Sherbourne CD, et al. Health-related quality of life in patients with human immunodeficiency virus infection in the United States: results from the HIV Cost and Services Utilization Study. Am J Med 2000; 108:714-22.
37. Molina JM, Orkin C, Iser DM, et al. All-oral therapy with sofosbuvir plus ribavirin for the treatment of HCV genotypes 1, 2, 3 and 4 infection in patients co-infected with HIV (PHOTON-2) [abstract MOAB0105LB]. Presented at: 20th International AIDS Conference, Melbourne, Australia, 2014.
38. Younossi ZM, Stepanova M, Zeuzem S, et al. Patient-reported outcomes assessment in chronic hepatitis C treated with sofosbuvir and ribavirin: The VALENCE study. J Hepatol 2014; 61:228-34.
39. Riley ED, Bangsberg DR, Perry S, Clark RA, Moss AR, Wu AW. Reliability and validity of the SF-36 in HIV-infected homeless and marginally housed individuals. Qual Life Res 2003; 12:1051-8.
40. Hsiung PC, Fang CT, Chang YY, Chen MY, Wang JD. Comparison of WHOQOL-bREF and SF-36 in patients with HIV infection. Qual Life Res 2005; 14:141-50.
41. Butt Z, Lai JS, Rao D, Heinemann AW, Bill A, Cella D. Measurement of fatigue in cancer, stroke, and HIV using the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) scale. J Psychosom Res 2013; 74:64-8.
42. Hays RD, Morales LS. The RAND-36 measure of health-related quality of life. Ann Med 2001; 33:350-7.
43. Webster K, Odom L, Peterman A, Lent L, Cella D. The Functional Assessment of Chronic Illness Therapy (FACIT) measurement system: Validation of version 4 of the core questionnaire. Quality Life Res 1999; 8:604.
44. Younossi ZM, Guyatt G, Kiwi M, Boparai N, King D. Development of a disease specific questionnaire to measure health related quality of life in patients with chronic liver disease. Gut 1999; 45:295-300.
45. Reilly MC, Zbrozek AS, Dukes EM. The validity and reproducibility of a work productivity and activity impairment instrument. PharmacoEconomics 1993; 4:353-65.
46. Brazier JE, Rowen D, Hanmer J. Revised SF-6D scoring programmes: A summary of improvements. PRO Newsletter 2008; 40(Fall):14-5.
47. Fleming CA, Christiansen D, Nunes D, et al. Health-related quality of life of patients with HIV disease: impact of hepatitis C coinfection. Clin Infect Dis 2004; 38:572-8.
48. Younossi Z, Stepanova M, Marcellin P, Afdhal N, Hunt S. Ledipasvir (LDV) and sofosbuvir (SOF) combination improves patient-reported outcomes (PRO) during treatment of chronic hepatitis C (CH-C) patients: results from the ION-1 clinical trial [abstract P1324]. Presented at: 49th Annual Meeting of European Association for the Study of the Liver, London, United Kingdom, 2014.
49. Younossi ZM, Stepanova M, Nader F, et al. Patient-reported outcomes in chronic hepatitis C patients with cirrhosis treated with sofosbuvircontaining regimens. Hepatology 2014; 59:2161-9.